CNCE

CTP-543

Alopecia Areata

Stage (next event)

Expected Date

Phase 3 Initiation

1H 2021

Catalyst Info & Data Links

TITLE: CTP-543 for Alopecia Areata - Phase 3 

  • ClinicalTrial.gov (NCT04518995): A Phase 3 Study to Evaluate the Efficacy and Safety of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata (THRIVE-AA1)


WHAT IS THE NEXT CATALYST EVENT?

  • THRIVE-AA2 Initiation 


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • 1H 2020


PRIOR DATA

PRESS RELEASES

Mechanism of Action

MECHANISM OF ACTION

  • CTP-543 is an oral selective inhibitor of Janus kinases JAK1 and JAK2. The FDA has granted CTP-543 Breakthrough Therapy designation for the treatment of adult patients with moderate to severe alopecia areata and Fast Track designation for the treatment of alopecia areata.

Updated by JM 

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

Incyte (INCY) appears to have the stronger hand in its patent disputes with Concert (CNCE), regardle

Incyte (INCY) appears to have the stronger hand in its patent disputes with Concert (CNCE), regardle

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon